Agoracom Blog Home

Author Archive

VIDEO – Valeo Pharma $VPH $VPHIF Drug Projected To Add $30M / Year Revenue Gets Ontario Public Drug Coverage $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 5:22 PM on Thursday, April 29th, 2021
http://blog.agoracom.com/wp-content/uploads/2021/03/VPH-square.jpg

Valeo Pharma is already a successful, revenue generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.

This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies. 

This model has resulted in the following success:

  • 2020 net revenues of $7.5 million
  • 2021 is expected to double to $15 million
  • Commercializing Novartis Asthma Therapies In Canada
  • Closed $6.6 Million Financing With Insiders Taking ~ 40% 

If that was all Valeo had, most investors would be happy to sit back and watch the Company grow.

But then came Redesca.  We are going to save you the science and tell you that Redesca belongs to a class of anticoagulant medications (blood thinners) called LMWH.  The size of the Canadian LMWH market is over $200M per year and Valeo believes they can capture 15-20% of this market.  If you’re doing back of napkin math, that equates to $30,000,000 – $40,000,000 per year in revenues.

But how does a new product capture that much market share?  Glad you asked because we asked CEO Steve Saviuk the same question.  Competition is tough in all markets and they don’t let someone take 15-20% market share without one hell of a fight.  Saviuk agreed and gave the following 3 reasons:

1.  Redesca has an 8-year international track record of safety and efficacy.  It is already well known

2. Redesca is flat out cheaper, which is music to the ears of Provincial Health Ministries whose budgets have been stretched to the max this year no thanks to COVID-19.  

Vaelo is so confident that it stated “This is great news for the Canadian healthcare system …. and is expected to help provide significant savings to provincial healthcare systems.”

More than just lip service, $VPH just announced that Redesca is now listed on the Ontario Public Drug Program, which means the government will cover its costs for all public use.  Moreover, $VPH expects additional Provinces to follow.   

If you love revenue generating, growing and blue sky potential small cap companies, then this Valeo interview is a must watch.

VIDEO – PlantX $VEGA.ca $PLTXF Nets Venus Williams as Ambassador, Launches 2K Products On Hudson’s Bay Marketplace $VERY.ca $MEAT.ca $EATS.ca $VEGN.ca

Posted by AGORACOM-JC at 4:20 PM on Wednesday, April 28th, 2021

The paradigm shifting, parabolic growth of plant based foods and a plant based life is unstoppable, with the plant-based food market alone expected to reach $74.2 billion by 2027.

PlantX Life (VEGA:CSE) (PLTXF:OTCQB) Is The One Stop Shop For Everything Plant Based + The  Digital Face of The Plant -Based Community   More than just lip service, $VEGA reported RECORD revenues of  $1,565,982 for March 2021 and $1,353,613 for February 2021.

The company announced Tennis Champion and Entrepreneur Venus Williams as Company Ambassador and if that’s not enough, they also launched Over 2000 Products on Hudson’s Bay Marketplace.

With a line up of plant based products and services that includes:

  • Plant Based Meal Delivery
  • Plant Based Snack Products
  • Plant Based Pet foods
  • Plant Based Restaurant Locator
  • Plant Based Recipes
  • Plant Based Essentials …. Like Chocolate (Essential?  You Bet)
  • And …… Plant Based …. PLANTS (It’s A BIG Business!)

If you believe in the massive paradigm shift towards plant based foods and more, be sure to watch and share this great interview with PlantX CEO Julia Frank.

VIDEO – HealthSpace Data Systems $HS.ca $HDSLF Tackles Teleconferencing Frustrations with “GovCall,” a Bespoke Telegov Solution for Government Agencies

Posted by AGORACOM-JC at 5:24 PM on Tuesday, April 27th, 2021
HealthSpace HS 300 x 300

HealthSpace Data Systems’ (CSE: HS) (OTCQB: HDSLF) (Frankfurt: 38H) “empowering government efficiency” solution has empowered the firm to become an industry leading tech pioneer, providing both enterprise- and mobile internet-based applications to more than 500 state and local government organizations in North America. Including in:

  • Sonoma County, California
  • Jackson County, Missouri
  • Illinois
  • Wisconsin
  • Ontario, Canada

Today, the company announced the planned launch of a new platform, GovCall

GovCall will be a leading teleconferencing platform focused exclusively on the government market.  In order to accomplish this, the Company has entered into an exclusive partnership agreement with Iotum Inc., a leader in teleconferencing and group communications.

HealthSpace currently offers the only integrated product suite to incorporate inspection, administration and analytics across all platforms in North America.

  • A cloud-based and mobile platform helps revolutionize every aspect of government regulatory work
  • including licensing and inspections, accounting, even disease surveillance.

And underpinning its innovation is a robust business model:

  • Scalable with Strong Pipeline of Organic Growth
  • Fully funded and built to execute on all-time high sales pipeline of >$18m and growing
  • Sticky and Diversified Customer Base: Over 98% client retention year-over-year
  • Predictable Recurring Revenues, targeting $10m (Over 100% from YE2020) in Annual Recurring Revenue within 12 to 18 months

HealthSpace CEO Silas Garrison breaks down how GovCall will work and what it will mean for the company:

AGORACOM Small Cap 60: What Is The Importance of The $HPQ.ca Gen1 PUREVAP Nano Silicon Reactor? $ENPH $BE $NNO $PYR

Posted by AGORACOM-JC at 4:22 PM on Tuesday, April 27th, 2021

VIDEO – Liquid Avatar $LQID Digital ID and Monetization Takes A Massive Step Forward With VISA Card Launch $MOS.ca $MOGO.ca $CTZ.ca

Posted by AGORACOM-JC at 6:40 PM on Monday, April 26th, 2021

When the Facebook data privacy scandal broke out, the world woke up to just how badly our individual data was being traded, used and most importantly, the amount of profit being generated by major corporations at our expense.

This led to the enactment of the biggest data privacy laws in history.  Specifically, General Data Protection Regulation (GDPR) out of Europe and the California Consumer Privacy Act (CCPA).

Enter LQID (formerly KABN).  The Company Turns The Problem Of Data Privacy Into A Profit For Individuals, While Providing Big Businesses With New & Compliant Business Models.

More than just lip service, $LQID has made some major announcements, including joining the Trust Over IP Foundation, which includes over 170 members including IBM, Mastercard, Accenture and many other global leaders who are defining a complete architecture for Internet-scale digital trust. 

Does that sound like a mouthful?  Yeah, it does.  But all you have to really understand for now is that digital ID, privacy and monetization is going to become a reality in the very near future.  Government regulations are enforcing it.  Consumers are demanding it and $LQID is delivering it at such an advanced scale that the Trust Over IP Foundation provided them with a strategic role as a Steering Member. 

If that wasn’t enough proof for you, Google  validated the $LQID business model with this stunning announcement at the beginning of March:  

Google announces major shift away from precision-targeting of ads based on everything you do on the internet

  • Google believes these types of tracking methods don’t “meet rising consumer expectations for privacy, nor will they stand up to rapidly evolving regulatory restrictions, and therefore aren’t a sustainable long term investment.”
  • Google is experimenting with tools in its Privacy Sandbox that are designed to allow advertising to continue to work on the web but in a less privacy-encroaching way.
  • “Keeping the internet open and accessible for everyone requires all of us to do more to protect privacy — and that means an end to not only third-party cookies, but also any technology used for tracking individual people as they browse the web,” David Temkin, Google’s director of product management for ads privacy and trust, 

 What is the potential outcome of this major shift by Google?

  “Google’s decision could upend the ad industry, which has relied on these types of tracking tools”  

Now the data privacy and monetization game is underway with LQID sitting in a great position within the industry and the dominant position within the small cap world.  That dominant position got even stronger today when $LQID announced the Launch Of KABN Prepaid Visa Card and Mobile Card App in Canada  

WHY IS THIS SO IMPORTANT?

If consumers are going to switch to Liquid Avatar to protect and monetize their identity, they are also going to need ways to pay for the great individualized offers presented to them, which means $LQID has just added another super valuable piece of the puzzle to its solution

Watch this interview with CEO David Lucatch for an even deeper discussion into what this all means for $LQID and YOU.

VIDEO – PPE specialist Maitri Health Technologies $MTEC Sets Eyes Overseas, with Prestigious UK Trade Invite, New Hires and Tech Innovation $DOC.ca $DOCRF $WELL.ca $PRN.ca

Posted by AGORACOM-JC at 7:02 PM on Sunday, April 25th, 2021
Maitri Health Technologies MTEC

Maitri Health Technologies is a global platform for healthcare supply security whose main focus provides a reliable source of certified PPE (personal protective equipment) and testing solutions through an onshore manufacturing model. 

This model has led to the creation of innovative and industry leading products including 3D certified surgical masks and patent-pending face shields, all integrated with technology to help track, trace and enable safer workplaces and communities.

It all takes place against a backdrop of huge potential: the global personal protective equipment market size is expected to reach USD 123.38 billion by 2027, registering a CAGR of 9.6%.

After previously securing Health Canada approval for its domestically manufactured N95 masks, the company has had a trio of big announcements over the course of the last month:

  • Maitri has been asked by the British Columbia Ministry of Jobs, Economic Recovery & Innovation to join a government-supported virtual trade mission to the United Kingdom.
  • Andrew McCann, a digital innovator in cloud platforms and online user experiences, and co-founder of DeviantArt, has joined the company as Chief Technology Officer.
  • Maitri has appointed Bridget Ross, CEO of Israel-based MedTech company ChroniSense Medical, to its Advisory Board.

Andrew Morton, Maitri’s CEO, talks us through the developments:

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:56 AM on Saturday, April 24th, 2021

A weekly summary of Novamind news and media

FEATURES April 23, 2021

Dr. Reid Robison on the Science of Psychedelics

Leafy interviews Novamind’s CMO about how these compounds influence our mind on a molecular level.

FEATURES April 21, 2021

Why Merck Chose Novamind to Lead a Groundbreaking Study

Our CEO and CMO spoke with Streetwise Reports about how Cedar Clinical Research is positioned to develop a new option for treatment-resistant depression.

OPINION April 21, 2021

How Modern Psychedelics Began with a Bike Ride

On April 19, 1943, chemist Albert Hofmann took .00005 teaspoons of LSD. As he rode his bicycle home, he realized that the world had just changed. By Novamind CMO, Dr. Reid Robison and Kirsten Hirst.

View all media

Novamind Collaborates with Center for Change

April 21, 2021

Novamind Presented at the Planet MicroCap Virtual Event on April 22, 2021

April 19, 2021

Novamind Increases Strategic Investment in Bionomics

April 13, 2021

View all press releases

Inside Ibogaine, One of the Most Promising and Perilous Psychedelics for Addiction

More Americans died from drug overdoses in 2020 than ever before. As psychedelic-assisted treatment options approach mainstream medicine, Time looks at ibogaine as a way to treat addiction like few treatments can.

Psychedelic Drug Worked As Well as Common Antidepressant, Small Trial Finds

Psilocybin works. Researchers in London released findings from a phase 2 trial indicating that a couple of doses of psilocybin may treat depression as well as one of the most commonly prescribed antidepressants. More research is required but leaders of the study were surprised with the outcome.

         Follow @novamind_inc on Instagram

VIDEO – PK Beans $BEAN The Female Powered Small Cap Joins Faire.com a Wholesale Marketplace to Grow Its Omni-Channel Distribution Model

Posted by AGORACOM-JC at 6:01 PM on Friday, April 23rd, 2021

PK Beans is a  revenue generating children’s wellness brand that is differentiating itself and super charging growth through great innovation and technology integration.

This is proven by the following:

  • Canada’s Only Public Company With Predominantly Female Board of Directors
  •  $1.5M in 2020 Sales
    • Over 18K orders in 2020
    • 55% increase in online visitors in 2020
  • 10,000 customers
  • Returning customer rate of 81.4%,
    • increase of 34.56% in average order values (AOV).
  • 790 affiliates
  • Awarded favourite brand (Jillian Harris Favourite Brand) Canadian television personality and interior designer.
  • Adventure subscription box. a monthly subscription that will help extend the PK Bean’s apparel brand into the childhood adventure play space
  • Launched its second-hand resale and sustainable initiative
  • Acquiring children’s health food company Les Petits Terribles Inc.

VIDEO – $HPQ.ca Silicon Production Milestone Moves Company Closer To Awaiting Battery Manufacturers and Automobile Manufacturers HPQFF $ENPH $BE $NNO $PYR

Posted by AGORACOM-JC at 4:42 PM on Friday, April 23rd, 2021

HPQ Silicon Resources $HPQ $HPQFF is a Quebec-based company that is developing a portfolio of high value-added silicon products sought after by battery and electric vehicle manufacturers.  

If that sounds a lot like what other small companies are saying lately, $HPQ differentiates itself as a leader of the pack thanks to the following: 

Yesterday, the Company announced a major milestone with this press release HPQ Gen1 Nano Silicon Reactor Exceeds Phase 1 Production Rate Target By 67%

To discuss the importance and the implications of this milestone, this excerpt from the press release says it all:

“Once the final equipment modifications are completed, the goal of the program will be to produce qualified samples which will then be tested by a third-party, the Institut National de Recherche Scientifique (INRS), and subsequently to awaiting battery manufacturers and automobile manufacturers.”

 Peter Pascali, President and CEO of PyroGenesis added a little more excitement when he stated

“It is even more exciting when one considers the impact this could have on addressing the challenges facing the EV battery space.”

Watch this great interview with $HPQ CEO Bernard Tourillon to get the full picture on next steps!

VIDEO – Cardiol Therapeutics $CRDL.ca $CRTPF is a Clinical-Stage Biotech Firm taking on the $30BN Heart Disease Healthcare Market via Cannabidiols and Cutting-Edge Anti-Inflammatory Therapies

Posted by AGORACOM-JC at 4:23 PM on Thursday, April 22nd, 2021

Cardiol Therapeutics $CRDL.ca $CRTPF is a groundbreaking, clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease (heart/blood vessels).

  • The company has received approval from the U.S. FDA to commence a Phase II/III, double-blind, placebo-controlled clinical trial investigating the efficacy and safety of its lead clinical product, CardiolRx™, in treating hospitalized COVID-19 patients with a prior history of, or risk factors for, cardiovascular disease (CVD).
  • CardiolRx™ is an ultra-pure, high concentration cannabidiol oral formulation that is pharmaceutically produced, manufactured under cGMP and THC free.

Cardiol is also planning a Phase II international trial of CardiolRx™ in acute myocarditis, a condition caused by inflammation in heart tissue, most common cause of sudden cardiac death in people under 35.

The company is also developing proprietary cannabidiol formulations for the treatment of chronic heart failure.

One such key development is its commercial product, Cortalex™, an extra-strength formulation (100 mg/mL concentration) of cannabidiol oil that is pharmaceutically produced to be free of THC. Cardiol believes Cortalex™ to be the purest form of cannabidiol oil available in Canada.

It is the first THC-free extra-strength formulation of cannabidiol oil available across Canada exclusively online at Medical Cannabis by Canada’s largest pharmacy retailer, Shoppers Drugs Mart.

  • In March 2020, Cardiol signed a supplier agreement to become a medical cannabidiol supplier to Shoppers Drug Mart. The retailer will supply Cardiol’s pharmaceutical cannabidiol products to Shoppers for sale in all provinces and territories in Canada through Shoppers’ online store, Medical Cannabis by Shoppers.

And there’s plenty more to write home about:

  • ~ $27M from exercise of warrants + equity raise since June 2020
  • Uplisting to NASDAQ
  • Team expansion with Chief Medical Officer hire

David Elsley, Cardiol Therapeutics’ President & CEO, gives us the low-down. Check it out: